The Canadian government has announced a contribution of up to $6.7 million to biotechnology firm Arch Biopartners to support the development of their drug MetaBlok (LSALT peptide), which aims to prevent organ inflammation in severe COVID-19 patients. The contribution will support phase II clinical trials to determine the drug’s ability to act against inflammation and identify optimal dosing. Funding comes from the federal government’s Strategic Innovation Fund (SIF).